These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 28504921)

  • 1. Plasminogen Activator Inhibitor-1 and Pericardial Fat in Individuals with Type 2 Diabetes Mellitus.
    Bayomy O; Rao AD; Garg R; Vaidya A; Kotin AR; Reiber B; Nijmeijer S; Di Carli MF; Jerosch-Herold M; Kwong RY; Adler GK
    Metab Syndr Relat Disord; 2017 Aug; 15(6):269-275. PubMed ID: 28504921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Re: "Plasminogen Activator Inhibitor-1 and Pericardial Fat in Individuals with Type 2 Diabetes Mellitus" by Bayomi et al. (Metab Syndr Relat Disord 2017;15:269-275).
    Avogaro A
    Metab Syndr Relat Disord; 2017 Aug; 15(6):266-268. PubMed ID: 28605281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma plasminogen activator inhibitor-I is associated with plasma leptin irrespective of body mass index, body fat mass, and plasma insulin and metabolic parameters in premenopausal women.
    De Mitrio V; De Pergola G; Vettor R; Marino R; Sciaraffia M; Pagano C; Scaraggi FA; Di Lorenzo L; Giorgino R
    Metabolism; 1999 Aug; 48(8):960-4. PubMed ID: 10459558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term beneficial effect of a 16-week very low calorie diet on pericardial fat in obese type 2 diabetes mellitus patients.
    Snel M; Jonker JT; Hammer S; Kerpershoek G; Lamb HJ; Meinders AE; Pijl H; de Roos A; Romijn JA; Smit JW; Jazet IM
    Obesity (Silver Spring); 2012 Aug; 20(8):1572-6. PubMed ID: 22282049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance.
    Hadigan C; Meigs JB; Rabe J; D'Agostino RB; Wilson PW; Lipinska I; Tofler GH; Grinspoon SS;
    J Clin Endocrinol Metab; 2001 Feb; 86(2):939-43. PubMed ID: 11158071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Visceral fat is a determinant of PAI-1 activity in diabetic and non-diabetic overweight and obese women.
    Mertens I; Van der Planken M; Corthouts B; Wauters M; Peiffer F; De Leeuw I; Van Gaal L
    Horm Metab Res; 2001 Oct; 33(10):602-7. PubMed ID: 11607880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adipocytokines and incident diabetes mellitus in older adults: the independent effect of plasminogen activator inhibitor 1.
    Kanaya AM; Wassel Fyr C; Vittinghoff E; Harris TB; Park SW; Goodpaster BH; Tylavsky F; Cummings SR
    Arch Intern Med; 2006 Feb; 166(3):350-6. PubMed ID: 16476877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.
    Kruszynska YT; Yu JG; Olefsky JM; Sobel BE
    Diabetes; 2000 Apr; 49(4):633-9. PubMed ID: 10871202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasminogen Activator Inhibitor-1 in poorly controlled vs well controlled Type-2 Diabetes Mellitus patients: A case-control study in a district hospital in Ghana.
    Nkansah C; Addai-Mensah O; Mensah K; Owusu M; Ephraim RKD; Adu P; Osei-Boakye F; Appiah SK; Serwaa D; Derigubah CA; Debrah AY
    PLoS One; 2021; 16(4):e0250090. PubMed ID: 33857223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasminogen activator inhibitor-1: a common denominator in obesity, diabetes and cardiovascular disease.
    De Taeye B; Smith LH; Vaughan DE
    Curr Opin Pharmacol; 2005 Apr; 5(2):149-54. PubMed ID: 15780823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasminogen activator inhibitor type 1 (PAI-1) in plasma and adipose tissue in HIV-associated lipodystrophy syndrome. Implications of adipokines.
    He G; Andersen O; Haugaard SB; Lihn AS; Pedersen SB; Madsbad S; Richelsen B
    Eur J Clin Invest; 2005 Sep; 35(9):583-90. PubMed ID: 16128865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proinsulin-like molecules and plasminogen activator inhibitor type 1 (PAI-1) activity in diabetic and non-diabetic subjects with and without myocardial infarction.
    Gray RP; Panahloo A; Mohamed-Ali V; Patterson DL; Yudkin JS
    Atherosclerosis; 1997 Apr; 130(1-2):171-8. PubMed ID: 9126661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasminogen activator inhibitor-1 and tissue-plasminogen activator in minority adolescents with type 2 diabetes and obesity.
    Umpaichitra V; Hussain MM; Castells S
    Pediatr Res; 2005 Sep; 58(3):483-7. PubMed ID: 15901895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epicardial adipose tissue thickness and type 2 diabetes risk according to the FINDRISC modified for Latin America.
    Lima-Martínez MM; Colmenares L; Campanelli Y; Paoli M; Rodney M; Santos RD; Iacobellis G
    Clin Investig Arterioscler; 2019; 31(1):15-22. PubMed ID: 30166212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pericardial rather than epicardial fat is a cardiometabolic risk marker: an MRI vs echo study.
    Sicari R; Sironi AM; Petz R; Frassi F; Chubuchny V; De Marchi D; Positano V; Lombardi M; Picano E; Gastaldelli A
    J Am Soc Echocardiogr; 2011 Oct; 24(10):1156-62. PubMed ID: 21795020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of insulin treatment on the balance between tissue plasminogen activator and plasminogen activator inhibitor-1 in type 2 diabetic patients.
    Vukovich T; Proidl S; Knöbl P; Teufelsbauer H; Schnack C; Schernthaner G
    Thromb Haemost; 1992 Sep; 68(3):253-6. PubMed ID: 1440487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epicardial fat thickness: relationship with plasma visfatin and plasminogen activator inhibitor-1 levels in visceral obesity.
    Malavazos AE; Ermetici F; Cereda E; Coman C; Locati M; Morricone L; Corsi MM; Ambrosi B
    Nutr Metab Cardiovasc Dis; 2008 Oct; 18(8):523-30. PubMed ID: 18083357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasminogen activator inhibitor-1 concentrations and bone mineral density in postmenopausal women with type 2 diabetes mellitus.
    Canecki-Varžić S; Prpić-Križevac I; Bilić-Ćurčić I
    BMC Endocr Disord; 2016 Mar; 16():14. PubMed ID: 26940634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 in non-obese type 2 diabetic patients.
    Kitagawa N; Yano Y; Gabazza EC; Bruno NE; Araki R; Matsumoto K; Katsuki A; Hori Y; Nakatani K; Taguchi O; Sumida Y; Suzuki K; Adachi Y
    Diabetes Res Clin Pract; 2006 Aug; 73(2):150-7. PubMed ID: 16458385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased plasminogen activator inhibitor-1 activity in offspring of type 2 diabetic patients: lack of association with plasma insulin levels.
    Gürlek A; Bayraktar M; Kirazli S
    Diabetes Care; 2000 Jan; 23(1):88-92. PubMed ID: 10857975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.